# RNN 1st Gen Model CVS Corporation Drug stores & proprietary stores

Stock predictor AI models:
72.73% successful of 55 deals
$ 84.48 Last close price
at 18-oct-2021


Model's trade recommendations 4.64% Return for period

-13.37% Annual return

$66.90B Market Cap

β 1.02  


Model (following trade recommendations)


Underlying stock

S&P 500

Return for period 4.64%
52wk return -20.66%
52wk Range
Sortino ratio -0.90
Sharpe ratio -0.85
Norm. RMSE 1.02%
Downside risk 14.88%
Volatility 0.00%
  • 2.00 (3.03%) Div (Yield)
  • STRONG BUY Analysts consensus recommendation

CVS Health Corporation is a pharmacy innovation company. Its offerings include pharmacy benefit management services, mail order, retail and specialty pharmacy, disease management programs, and retail clinics. The Company serves employers, insurance companies, unions, government employee groups, managed care organizations and other sponsors of health benefit plans, and individuals under the CVS Caremark Pharmacy Services, Caremark, CVS Caremark, CarePlus CVS/pharmacy, RxAmerica, Accordant, SilverScript, and Novologix names. CVS Health Corporation, formerly known as CVS Caremark Corporation, is headquartered in Woonsocket, Rhode Island.

Industry sector: Retail/Wholesale

Sector classification: Drug stores & proprietary stores

Deep Learning based analysis and prediction model for CVS Corporation (CVS) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 2, 2015.

Market data for CVS model training are being downloaded from the Quandl premium datasets on a daily basis.
Risks related to the novel coronavirus disease 2019 (COVID-19) caused by the virus named “SARS-CoV-2” are accounted for in this model in the form of the historical data coincided with outbreaks and other global events in the past used to train ML prediction model for CVS.

Model is being retrained on a daily basis.

Float 1009M
P/E 10.58
Shares Outstanding 1015M
% Held by Insiders 0.53%
% Held by Institutions 84.03%
EPS (last reported FY) $5.90
EPS (last reported Q) $1.48
EPS, estimated (last reported Q) $1.39
Total revenues $185 B
Net income $7 B